Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

Autor(es):Mostrar menos -

Medeiros-Ribeiro, Ana C. ^[1] ; Aikawa, Nadia E. ^{[1, 2]} ; Saad, Carla G. S. ^[1] ; Yuki, Emily F. N. ^[1] ; Pedrosa, Tatiana ^[1] ; Fusco, Solange R. G. ^[1] ; Rojo, Priscila T. ^[1] ; Pereira, Rosa M. R. ^[1] ; Shinjo, Samuel K. ^[1] ; Andrade, Danieli C. O. ^[1] ; Sampaio-Barros, Percival D. ^[1] ; Ribeiro, Carolina T. ^[1] ; Deveza, Giordano B. H. ^[1] ; Martins, Victor A. O. ^[1] ; Silva, Clovis A. ^[2] ; Lopes, Marta H. ^[3] ; Duarte, Alberto J. S. ^[4] ; Antonangelo, Leila ^[4] ; Sabino, Ester C. ^{[5, 3]} ; Kallas, Esper G. ^[3] ; Pasoto, Sandra G. ^[1] ; Bonfa, Eloisa ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Hosp Clin HCFMUSP, Rheumatol Div, Fac Med, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Inst Crianca, Hosp Clin HCFMUSP, Pediat Rheumatol Unit, Fac Med, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Hosp Clin HCFMUSP, Infect Dis Dept, Fac Med, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Hosp Clin HCFMUSP, Cent Lab Div, Fac Med, Sao Paulo - Brazil

^[5] Univ Sao Paulo, Inst Med Trop, Fac Med, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Nature Medicine; v. 27, n. 10 JUL 2021.
• Citações Web of Science: 25

Resumo

CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in several countries. However, its immunogenicity in immunocompromised individuals has not been well established. We initiated a prospective phase 4 controlled trial (no. NCT04754698, CoronavRheum) in 910 adults with autoimmune rheumatic diseases (ARD) and 182 age- and sex-frequency-matched healthy adults (control group, CG), who received two doses of CoronaVac. The primary outcomes were reduction of >= 15% in both anti-SARS-CoV-2 IgG seroconversion (SC) and neutralizing antibody (NAb) positivity 6 weeks (day 69 (D69)) after the second dose in the ARD group compared with that in the CG. Secondary outcomes were IgG SC and NAb positivity at D28, IgG titers and neutralizing activity at D28 and D69 and vaccine safety. Prespecified endpoints were met, with lower anti-SARS-Cov-2 IgG SC (70.4 versus 95.5%, P < 0.001) and NAb positivity (56.3 versus 79.3%, P < 0.001) at D69 in the ARD group than in the CG. Moreover, IgG titers (12.1 versus 29.7, P < 0.001) and median neutralization activity (58.7 versus 64.5%, P = 0.013) were also lower at D69 in patients with ARD. At D28, patients with ARD presented with lower IgG frequency (18.7 versus 34.6%, P < 0.001) and NAb positivity (20.6 versus 36.3%, P < 0.001) than that of the CG. There were no moderate/severe adverse events. These data support the use of CoronaVac in patients with ARD, suggesting reduced but acceptable short-term immunogenicity. The trial is still ongoing to evaluate the long-term effectiveness/immunogenicity. In a large prospective phase 4 trial, vaccination with CoronaVac, an inactivated SARS-CoV-2 vaccine, elicited significantly lower virus-specific IgG antibodies and neutralizing antibodies in patients with autoimmune rheumatic diseases than in age- and sex-matched healthy control trial participants. (AU)

• Processo FAPESP: 18/09937-9 - Análise do perfil imune da saliva e soro dos pacientes com Síndrome de Sjogren primária
• Beneficiário: Victor Adriano de Oliveira Martins
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 17/14352-7 - Avaliação da relevância dos níveis sanguíneos de drogas utilizadas em doenças autoimunes reumatológicas no acompanhamento da segurança, eficácia e aderência à terapêutica
• Beneficiário: Tatiana Do Nascimento Pedrosa
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 19/21173-7 - Avaliação do tratamento do lúpus eritematoso cutâneo com talidomida: fatores clínicos, laboratoriais e histológicos associados à resposta clínica e efeitos adversos
• Beneficiário: Carolina Torres Ribeiro
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 15/03756-4 - Avaliação da relevância dos níveis sanguíneos de drogas utilizadas em doenças autoimunes reumatológicas no acompanhamento da segurança, eficácia e aderência à terapêutica
• Beneficiário: Eloisa Silva Dutra de Oliveira Bonfá
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 20/11677-5 - Análise do perfil imune da saliva e soro dos pacientes com Síndrome de Sjögren primária
• Beneficiário: Giordano Bruno Henriques Deveza
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica